Cover Image
Market Research Report

Europe DIABETES DRUGS MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 618294
Published Content info 66 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe DIABETES DRUGS MARKET FORECAST 2018-2026
Published: April 9, 2018 Content info: 66 Pages
Description

KEY FINDINGS

The Europe diabetes drug market is expected to progress with a 5.08% CAGR over the forecast years of 2018-2026. It is the second largest market for diabetes drugs.

MARKET INSIGHTS

An increase in life-expectancy and growing prevalence of diabetes in the population are factors driving growth in the European diabetes drug market. The development of new formulations and increasing research and development are factors presenting the market with lucrative growth opportunities. However, fierce market competition and rising concerns in scientific community could restrain the market expansion.

COMPETITIVE INSIGHTS

Some of the well-known diabetes drug manufacturing companies include AstraZeneca Plc, GlaxoSmithKline, Xeris Pharmaceuticals, Eli Lilly And Company, B.Braun Melsungen Ag, Novo Nordisk A/S, Pfizer, Albireo Pharma Inc, Macrogenics Inc, Astellas and Merck.

Table of Contents
Product Code: 16327

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. RISING PREVALENCE OF TYPE 2 DIABETES
    • 3.2.2. INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE

4. MARKET DYNAMICS

  • 4.1. ETYMOLOGY OF DIABETES DRUGS MARKET
  • 4.2. MARKET DEFINITION AND SCOPE
  • 4.3. LEGAL, POLICY AND REGULATORY ISSUES
  • 4.4. MARKET DRIVERS
    • 4.4.1. INCREASE IN PREVALENCE OF DIABETES
    • 4.4.2. ADVANCES IN INSULIN TECHNOLOGY
    • 4.4.3. GROWING ELDERLY POPULATION
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
    • 4.5.2. LACK OF AWARENESS AMONG PEOPLE
    • 4.5.3. COST SENSITIVITY ISSUES
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. DEVELOPMENT OF NEW FORMULATIONS
    • 4.6.2. INCREASING RESEARCH AND DEVELOPMENT
  • 4.7. MARKET CHALLENGES
    • 4.7.1. FIERCE MARKET COMPETITION
    • 4.7.2. RISING CONCERNS IN SCIENTIFIC COMMUNITY
    • 4.7.3. GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
    • 4.7.4. POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN

5. MARKET BY DIABETES TYPE

  • 5.1. TYPE 1
  • 5.2. TYPE 2

6. MARKET BY PRODUCT CLASS

  • 6.1. INSULIN
    • 6.1.1. FAST ACTING INSULIN
    • 6.1.2. INTERMEDIATE ACTING INSULIN
    • 6.1.3. LONG-ACTING INSULIN
  • 6.2. NON INSULIN
    • 6.2.1. DPP-4 INHIBITOR
    • 6.2.2. GLP-1 RECEPTORS AGONISTS
    • 6.2.3. SGLT-2 INHIBITORS
    • 6.2.4. OTHERS

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. OPPORTUNITY MATRIX
  • 7.3. VENDOR LANDSCAPE
  • 7.4. PIPELINE ANALYSIS
  • 7.5. KEY BUYING CRITERIA
    • 7.5.1. SAFETY AND EFFICACY
    • 7.5.2. AVAILABILITY
    • 7.5.3. LONG TERM RELIEF
    • 7.5.4. AFFORDABILITY AND COST-EFFECTIVENESS
    • 7.5.5. REIMBURSEMENT OF PRESCRIPTION DRUGS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. EUROPE
    • 8.1.1. UNITED KINGDOM
    • 8.1.2. FRANCE
    • 8.1.3. GERMANY
    • 8.1.4. RUSSIA
    • 8.1.5. ITALY
    • 8.1.6. DENMARK
    • 8.1.7. NORWAY
    • 8.1.8. AUSTRIA
    • 8.1.9. SWITZERLAND
    • 8.1.10. SWEDEN
    • 8.1.11. NETHERLANDS
    • 8.1.12. REST OF EUROPE

9. COMPANY PROFILES

  • 9.1. ELI LILLY AND COMPANY
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. SWOT ANALYSIS
    • 9.1.4. STRATEGIC INITIATIVES
  • 9.2. ASTRAZENECA PLC.
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. SWOT ANALYSIS
    • 9.2.4. STRATEGIC INITIATIVES
  • 9.3. B.BRAUN MELSUNGEN AG
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SWOT ANALYSIS
    • 9.3.4. STRATEGIC INITIATIVES
  • 9.4. NOVO NORDISK A/S
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. SWOT ANALYSIS
    • 9.4.4. STRATEGIC INITIATIVES
  • 9.5. SANOFI
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SWOT ANALYSIS
    • 9.5.4. STRATEGIC INITIATIVES
  • 9.6. DIAVACS, INC.
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SWOT ANALYSIS
  • 9.7. XOMA CORP.
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SWOT ANALYSIS
    • 9.7.4. STRATEGIC INITIATIVES
  • 9.8. ALBIREO PHARMA INC.
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SWOT ANALYSIS
  • 9.9. MACROGENICS, INC.
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SWOT ANALYSIS
  • 9.10. ASTELLAS PHARMA
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SWOT ANALYSIS
    • 9.10.4. STRATEGIC INITIATIVES
  • 9.11. GLAXOSMITHKLINE
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SWOT ANALYSIS
  • 9.12. MERCK
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SWOT ANALYSIS
    • 9.12.4. STRATEGIC INITIATIVES
  • 9.13. PFIZER
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SWOT ANALYSIS
    • 9.13.4. STRATEGIC INITIATIVES
  • 9.14. XERIS PHARMACEUTICALS
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SWOT ANALYSIS
    • 9.14.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1: EUROPE DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ BILLION)
  • TABLE 2: REGULATORY FRAMEWORK IN DIABETES DRUGS MARKET
  • TABLE 3: EUROPE DIABETES DRUGS MARKET, BY DIABETES TYPES, 2018-2026, (IN $ BILLION)
  • TABLE 4: EUROPE DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 5: EUROPE DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLIONS)
  • TABLE 6: EUROPE DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLIONS)
  • TABLE 7: EUROPE DIABETES DRUGS MARKET, BY INSULIN TYPE, 2018-2026, (IN $ BILLION)
  • TABLE 8: EUROPE DIABETES DRUGS MARKET, BY NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • TABLE 9: OPPORTUNITY MATRIX FOR DIABETES DRUGS MARKET
  • TABLE 10: VENDOR LANDSCAPE OF DIABETES DRUGS MARKET
  • TABLE 11: PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
  • TABLE 12: EUROPE DIABETES DRUGS MARKET, BY GEOGRAPHY, 2018-2026, (IN $ BILLION)
  • TABLE 13: EUROPE DIABETES DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ BILLION)

LIST OF FIGURES

  • FIGURE 1: EUROPE DIABETES DRUGS MARKET 2018-2026 (IN $ BILLION)
  • FIGURE 2: EUROPE DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 3: EUROPE DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 4: AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY CONTINENT AND GENDER (IN YEARS)
  • FIGURE 5: EUROPE DIABETES DRUGS MARKET, BY DIABETES TYPE, 2017 & 2026 (IN %)
  • FIGURE 6: EUROPE DIABETES DRUGS MARKET, BY TYPE 1 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 7: EUROPE DIABETES DRUGS MARKET, BY TYPE 2 DIABETES, 2018-2026 (IN $ BILLION)
  • FIGURE 8: EUROPE DIABETES DRUGS MARKET, BY PRODUCT CLASS, 2018-2026 (IN $ BILLION)
  • FIGURE 9: EUROPE DIABETES DRUGS MARKET, BY INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 10: EUROPE DIABETES DRUGS MARKET, BY FAST ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 11: EUROPE DIABETES DRUGS MARKET, BY INTERMEDIATE ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 12: EUROPE DIABETES DRUGS MARKET, BY LONG ACTING INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 13: EUROPE DIABETES DRUGS MARKET, BY NON-INSULIN, 2018-2026 (IN $ BILLION)
  • FIGURE 14: EUROPE DIABETES DRUGS MARKET, BY DPP-4 INHIBITOR, 2018-2026 (IN $ BILLION)
  • FIGURE 15: EUROPE DIABETES DRUGS MARKET, BY GLP-1 RECEPTORS AGONISTS, 2018-2026 (IN $ BILLION)
  • FIGURE 16: EUROPE DIABETES DRUGS MARKET, BY SGLT-2 INHIBITORS, 2018-2026 (IN $ BILLION)
  • FIGURE 17: EUROPE DIABETES DRUGS MARKET, BY OTHER NON INSULIN DRUGS, 2018-2026 (IN $ BILLION)
  • FIGURE 18: PORTER'S FIVE FORCE MODEL OF DIABETES DRUGS MARKET
  • FIGURE 19: KEY BUYING IMPACT ANALYSIS
  • FIGURE 20: EUROPE DIABETES DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
  • FIGURE 21: EUROPE DIABETES DRUGS MARKET, 2017 & 2026 (IN %)
  • FIGURE 22: UNITED KINGDOM DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 23: FRANCE DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 24: GERMANY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 25: RUSSIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 26: ITALY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 27: DENMARK DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 28: NORWAY DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 29: AUSTRIA DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 30: SWITZERLAND DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 31: SWEDEN DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 32: NETHERLANDS DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
  • FIGURE 33: REST OF EUROPE DIABETES DRUGS MARKET, 2018-2026 (IN $ BILLION)
Back to Top